ECO Animal Health and Ghent University sign poultry vaccine development licensing deal

ECO Animal Health Ltd (ECO) has entered a worldwide exclusive development and licensing deal with Ghent University-PROVAXS.

This deal allows ECO to further develop, register and commercialize a Clostridium perfringens vaccine for poultry based on antigens co-developed by Prof. Filip Van Immerseel (Laboratory of Bacteriology, Faculty of Veterinary Medicine Ghent University) and Prof. Rick Titball (College of Life and Environmental Sciences, University of Exeter).

Clostridium perfringens is a bacterium which normally inhabits the gastrointestinal system but when predisposing triggers are present, specific strains can cause necrotic enteritis with major consequences for bird health and growth.

Peter Lawrence of ECO Animal Health Group plc commented, “We are delighted to have entered into this collaboration with Ghent University. Necrotic enteritis can result in a significant reduction in body weight and increase in feed conversion rate when compared with healthy broilers”.

Professor Filip Van Immerseel Ghent University is looking forward to the collaboration with ECO Animal Health: "The development of this candidate vaccine into a practical tool for the prevention of necrotic enteritis will support the global poultry industry in adopting a sustainable approach to the management of this disease”.

ECO Animal Health, based in London, is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel antimicrobial, Aivlosin, as well as a range of generic therapeutic products.

More information: Sven Arnouts: business developer PROVAXS, +32 (0)9 264 73 33